The lastest clinical triales: cervix

سال انتشار: 1403
محل انتشار: دومین کنگره بین المللی کنسرژنومیکس
کد COI اختصاصی: ICGCS02_119
زبان مقاله: انگلیسی
تعداد مشاهده: 102

نویسندگان

Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran

چکیده

Cervical cancer remains a significant health challenge worldwide, particularly in low- and middle-income countries where access to early detection and effective treatment options is often limited. The burden of this disease is felt most acutely in regions with limited healthcare infrastructure, where routine screening programs and advanced medical treatments may not be readily available. However, recent clinical trials have brought forth promising advancements in the prevention, screening, and treatment of cervical cancer, providing new hope for patients, especially those with recurrent or metastatic disease. One of the most notable advancements is the FDA's approval of Tivdak (tisotumab vedotin-tftv), an innovative antibody-drug conjugate. Clinical trials have demonstrated that Tivdak significantly improves overall survival rates in patients with advanced cervical cancer, offering an extension in median survival compared to traditional chemotherapy treatments. This represents a significant breakthrough for patients with limited treatment options, as it provides an alternative for those who have not responded well to standard therapies. Tivdak’s mechanism of targeting and delivering a cytotoxic agent directly to cancer cells marks a new era in targeted therapies for cervical cancer. In addition to Tivdak, combination therapies have also shown great promise. Pembrolizumab (Keytruda), in combination with chemotherapy, with or without bevacizumab, has emerged as an effective treatment for persistent, recurrent, or metastatic cervical cancer. Research indicates that this combination significantly improves both overall survival and progression-free survival, providing patients with more robust options to manage advanced-stage cervical cancer. The use of immunotherapy, like pembrolizumab, highlights the growing role of the immune system in cancer treatment, offering a more tailored approach to combatting the disease. On the preventive side, efforts have also made remarkable strides. Innovations in HPV vaccination, such as the development of more accessible and cost-effective vaccines, continue to play a crucial role in reducing cervical cancer incidence. The introduction of newer vaccines that cover more strains of HPV has the potential to prevent even more cases of cervical cancer. Moreover, self-sampling technologies for HPV detection, including home-based HPV testing kits, are improving access to screening, especially in underserved regions where healthcare resources are limited. These tests offer a more private and convenient option for women who may face barriers to traditional clinic-based screening methods. These advancements underscore the importance of ongoing clinical trials and research in cervical cancer. By broadening access to these new therapies and preventive measures, there is potential to drastically reduce the incidence and mortality rates associated with cervical cancer, improving the quality of life for patients globally. Continued investment in clinical trials, along with efforts to make these innovations more accessible, is essential to combating cervical cancer on a global scale, particularly in resource-limited settings.

کلیدواژه ها

Cervical cancer, chemotherapy, antibody-drug conjugate, clinical trials, survival rates

مقالات مرتبط جدید

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.